Deciphera Pharmaceuticals (NASDAQ:DCPH) Shares Up 6.6%

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shot up 6.6% during trading on Tuesday . The stock traded as high as $34.52 and last traded at $34.43. 9,430 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 408,984 shares. The stock had previously closed at $32.30.

Several research firms have recently commented on DCPH. Zacks Investment Research raised shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating and set a $35.00 price objective for the company in a research note on Friday, September 24th. Truist Securities decreased their price target on shares of Deciphera Pharmaceuticals from $84.00 to $65.00 and set a “buy” rating for the company in a research note on Monday, October 4th. HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of Deciphera Pharmaceuticals in a research note on Monday, September 20th. Stifel Nicolaus started coverage on shares of Deciphera Pharmaceuticals in a research note on Wednesday, September 29th. They issued a “buy” rating for the company. Finally, Truist decreased their price target on shares of Deciphera Pharmaceuticals from $84.00 to $65.00 and set a “buy” rating for the company in a research note on Monday, October 4th. They noted that the move was a valuation call. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Deciphera Pharmaceuticals has an average rating of “Buy” and an average target price of $65.30.

The firm has a market cap of $2.05 billion, a PE ratio of -7.83 and a beta of 1.42. The firm’s 50-day moving average price is $31.39 and its two-hundred day moving average price is $35.35.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings data on Tuesday, August 3rd. The company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.06). The company had revenue of $23.57 million for the quarter, compared to analysts’ expectations of $22.25 million. Deciphera Pharmaceuticals had a negative return on equity of 50.07% and a negative net margin of 308.58%. On average, research analysts expect that Deciphera Pharmaceuticals, Inc. will post -4.87 EPS for the current year.

In other news, EVP Matthew L. Sherman sold 2,659 shares of Deciphera Pharmaceuticals stock in a transaction on Monday, October 4th. The shares were sold at an average price of $33.17, for a total value of $88,199.03. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 4.10% of the company’s stock.

Several institutional investors have recently made changes to their positions in DCPH. Lazard Asset Management LLC acquired a new position in shares of Deciphera Pharmaceuticals in the 1st quarter valued at $45,000. Macquarie Group Ltd. increased its stake in Deciphera Pharmaceuticals by 90.8% in the 2nd quarter. Macquarie Group Ltd. now owns 2,005 shares of the company’s stock valued at $73,000 after buying an additional 954 shares during the period. Eaton Vance Management acquired a new position in Deciphera Pharmaceuticals in the 1st quarter valued at $79,000. Royal Bank of Canada increased its stake in Deciphera Pharmaceuticals by 8,556.0% in the 1st quarter. Royal Bank of Canada now owns 2,164 shares of the company’s stock valued at $97,000 after buying an additional 2,139 shares during the period. Finally, E Fund Management Co. Ltd. acquired a new position in Deciphera Pharmaceuticals in the 1st quarter valued at $144,000. 73.67% of the stock is currently owned by institutional investors and hedge funds.

Deciphera Pharmaceuticals Company Profile (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors.

Read More: Capital gains and your 401(k) or IRA

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.